2. Signaling Pathways
  3. Anti-infection
  4. HBV

HBV

Hepatitis B virus

HBV

Related Products

PDF 0.42 MB

HBV (Hepatitis B virus), abbreviated HBV, is a species of the genus Orthohepadnavirus, which is likewise a part of the Hepadnaviridae family of viruses. HBV causes the disease hepatitis B. The hepatitis B virus is classified as the type species of the Orthohepadnavirus, which contains three other species: the Ground squirrel hepatitis virus, Woodchuck hepatitis virus, and theWoolly monkey hepatitis B virus. The genus is classified as part of the Hepadnaviridae family. HBV is divided into four major serotypes (adr, adw, ayr, ayw) based on antigenic epitopes present on its envelope proteins, and into eight genotypes (A–H) according to overall nucleotide sequence variation of the genome. The genotypes have a distinct geographical distribution and are used in tracing the evolution and transmission of the virus. Differences between genotypes affect the disease severity, course and likelihood of complications, and response to treatment and possibly vaccination.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-105098
    Lobucavir
    		Inhibitor
    Lobucavir (BMS-180194; SQ 34514)，a nucleoside analogue，is an antiviral agent. Lobucavir shows a broad spectrum of activity against HBV，HIV/AIDS，and α，β，and γ herpes viruses including CMV，herpes-simplex，varicella-zoster，and Epstein-Barr virus.
    Lobucavir
  • HY-148171
    L-2'-Fd4C
    		Inhibitor
    L-2'-Fd4C, is an l-nucleoside analogue. L-2'-Fd4C has anti-human immunodeficiency virus (HIV) and anti-hepatitis B virus (HBV) activity.
    L-2'-Fd4C
  • HY-145050
    HBV-IN-7
    		Inhibitor
    HBV-IN-7 is a potent HBV inhibitor with an EC50 of 7 nM (WO2021213445A1, compound 5).
    HBV-IN-7
  • HY-145051
    HBV-IN-8
    		Inhibitor
    HBV-IN-8 is a potent HBV inhibitor with an EC50 of 287.9 nM (WO2021213445A1, compound 13).
    HBV-IN-8
  • HY-13910R
    Tenofovir (Standard)
    		Inhibitor
    Tenofovir (Standard) is the analytical standard of Tenofovir. This product is intended for research and analytical applications. Tenofovir (GS 1278) is a nucleotide reverse transcriptase inhibitor to treat HIV and chronic Hepatitis B (HBV).
    Tenofovir (Standard)
  • HY-156703S
    HBV-IN-39-d3
    		Inhibitor
    HBV-IN-39-d3 (Example 14) is a deuterated HBV-IN-39 (Example 13). HBV-IN-39 is an HBV inhibitor. HBV-IN-39-d3 has better oral bioavailability than HBV-IN-39.
    HBV-IN-39-d<sub>3</sub>
  • HY-P99541
    Tuvirumab
    		Inhibitor
    Tuvirumab (OST 577; SDZ-OST 577) is a human IgG1 subclass monoclonal antibody directed against HBV surface antigen (HBsAg). Tuvirumab binds specifically and with high affinity (K=3.6 nM) to HBsAg. Tuvirumab has the potential for chronic hepatitis B research.
    Tuvirumab
  • HY-147321
    3'-DMTr-dG(iBu)
    3'-DMTr-dG(iBu) is a nucleoside for the synthesis of nucleic acid, such as antiviral agents used in the research of viral infection (HBV, HDV), and oligonucleotides against Alzheimer’s disease and other tauopathies.
    3'-DMTr-dG(iBu)
  • HY-145053A
    (5S,8R)-HBV-IN-10
    		Inhibitor
    (5S,8R)-HBV-IN-10 is an enantiomer of compound 6 (WO2021204258A1). Compound 6 is a hepatitis B surface antigen (HBsAg) inhibitor (0.001 μM< EC50 ≤0.05 μM). From patent WO2021204258A1, compound 6.
    (5S,8R)-HBV-IN-10
  • HY-P4042
    Hepatitis B Virus Receptor Binding Fragment
    		Inhibitor
    Hepatitis B Virus Receptor Binding Fragment (hepatitis B peptide 4980) is a synthetic peptide analog which specifically binds to Hep G2 cells. Hepatitis B Virus Receptor Binding Fragment is a promising immunogen expected to elicit protective antibodies based on the concept of the attachment blockade pathway of virus neutralization.
    Hepatitis B Virus Receptor Binding Fragment
  • HY-131603
    Lamivudine triphosphate
    		Inhibitor
    Lamivudine triphosphate (3TCTP) is a phosphorylated Lamivudine (HY-B0250) (a nucleoside analogue). Lamivudine triphosphate inhibits the Reverse Transcriptase of HIV or HBV viruses to block viral replication by chain termination. Lamivudine triphosphate is also an inhibitor of the RdRp activity of the NS5B subunit of the HCV. Lamivudine triphosphate can be incorporated into the nascent RNA by the SARS-CoV-2 RdRp, thus halting mutations in the nascent SARS-CoV-2 RNA.
    Lamivudine triphosphate
  • HY-145713
    GS-8873
    		Inhibitor
    GS-8873 is an orally active inhibitor for the production of hepatitis B virus (HBV) surface antigen (HBsAg) with an EC50 of 4 nM. GS-8873 exhibits good pharmacokinetic characters in rats and metabolic stability in human hepatocytes. GS-8873 causes neurofunctional deficits in rats and cynomolgus monkeys.
    GS-8873
  • HY-132603A
    AB-729 sodium
    		Inhibitor
    AB-729 sodium is a siRNA specifically designed to inhibit viral replication and reduces HBV antigens. AB-729 conjugates to a trimer of N-acetylgalactosamine (GalNAc) ligand that promotes uptake into hepatocytes via the asialoglycoprotein receptor (ASGR).
    AB-729 sodium
  • HY-148781
    HBV-IN-30
    		Inhibitor
    HBV-IN-30 (ex44), a flavone derivative, is a potent covalently closed circular DNA (cccDNA) inhibitor. cccDNA serves as the template for viral RNA transcription and subsequent viral DNA generation. HBV-IN-30 has the potential for the research of HBV infection.
    HBV-IN-30
  • HY-161327
    HBV-IN-44
    		Inhibitor
    HBV-IN-44 (Compound (S)-2a) is a HBV inhibitor with a IC50 value of 23 nM for HbsAg. HBV-IN-44 is less toxic to the neurite growth of HT22 cells and DRG neurons in vitro.
    HBV-IN-44
  • HY-112142A
    (Rac)-AB-423
    		Inhibitor
    (Rac)-AB-423 (DVR-23) is an anti-HBV candidate compound with promising anti-HBV activity. (Rac)-AB-423 showed no induction of CYP1A2, CYP3A4, or CYP2B6 enzyme activity at high concentrations. (Rac)-AB-423 exhibited desirable pharmacokinetic properties, enabling good systemic exposure and high oral bioavailability. (Rac)-AB-423 achieved more than 2 log viral load reduction in the hydrodynamic injection (HDI) HBV mouse model.
    (Rac)-AB-423
  • HY-124364
    RO6889678
    		Inhibitor
    RO6889678 is a highly potent HBV capsid formation inhibitor with a complex absorption, distribution, metabolism, and excretion (ADME) profile. RO6889678 is a potent inducer of CYP3A4 and coregulated proteins in human hepatocytes. RO6889678 is metabolized by a combination of CYP3A4-mediated oxidation and UDP-glucuronosyltransferase UGT1A3- and UGT1A1-mediated direct glucuronidation.
    RO6889678
  • HY-N2988
    Schisanwilsonin C
    		Inhibitor
    Schisanwilsonin C (Arisanschinin K) shows anti-HBV activity.
    Schisanwilsonin C
  • HY-13623C
    (1R,3S,4R)-ent-Entecavir
    		Control
    (1R,3S,4R)-ent-Entecavir ((1R,3S,4R)-ent-BMS200475; (1R,3S,4R)-ent-SQ34676) can be used to synthesize PROTAC targets to degrade deoxyribonucleic acid (DNA) polymerase.
    (1R,3S,4R)-ent-Entecavir
  • HY-P4048
    HBV Seq1 aa:93-100
    HBV Seq1 aa:93-100 is a hepatitis B virus (HBV) core antigen 93-100 peptide fragment.
    HBV Seq1 aa:93-100
Cat. No. Product Name / Synonyms Application Reactivity